Clinical Trial Update: A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer [Phase 2]

View source ↗

Summary

This document reports a completed Phase 2 feasibility study evaluating gefitinib (Iressa) in resistant cytokeratin-positive circulating tumor cells in the blood…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: University Hospital of Crete | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED